The prevention of analgesic opioids abuse: Expert opinion

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 21, 2015, Pages 4203-4206

  Maremmani, I ^a   Gerra, G ^b   Ripamonti, I C ^c   Mugelli, A ^d   Allegri, M ^e   Vigano R ^f   Romualdi, P ^g   Pinto, C ^h   Raffaeli, W ⁱ   Coluzzi, F ^j   GAtti, R C ^k   Mammucari, M ^l   Fanelli, G ^e  

^a UNIVERSITY OF PISA   (Italy)

^b United Nations Office on Drugs and Crime Austria   (Austria)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF PARMA   (Italy)

^f ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h S MARIA NUOVA HOSPITAL   (Italy)

ⁱ ISAL   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k ASL di Milano   (Italy)

^l ASL RM/E   (Italy)

more..

Author keywords

Addiction; Chronic pain; Doctor patient relationship; Opioid; Pain management

Indexed keywords

OPIATE; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ARTICLE; CHRONIC PAIN; DOCTOR PATIENT RELATION; HEALTH CARE PERSONNEL; HUMAN; OPIATE ADDICTION; PRESCRIPTION; EXPERT WITNESS; OPIOID-RELATED DISORDERS; PAIN; PROCEDURES; STANDARDS;

ANALGESICS, OPIOID; EXPERT TESTIMONY; HUMANS; OPIOID-RELATED DISORDERS; PAIN; PAIN MANAGEMENT; PHYSICIAN-PATIENT RELATIONS;

EID: 84956697180     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. INTERNATIONAL PAIN SUMMIT OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN. Declaration of Montréal: declaration that access to pain management is a fundamental human right. J Pain Palliat Care Pharmacother 2011; 25: 29-31.
2. Access to controlled drugs for medical purpose available at http://www.unodc.org/unodc/en/drugprevention-and-treatment/access-to-controlleddrugs-for-medical-purposes.html. Last access the 10th May, 2015.
3. WORLD HEALTH ORGANIZATION. Cancer pain relief. Geneva: World Health Organization, 1986.
4. SCOTTISH INTERCOLLEGIATE GUIDELINES NETWORK CONTROL OF PAIN IN ADULTS WITH CANCER. A national clinical guideline. SIGN - Scottish Intercollegiate Guidelines Network, November 2008.
5. CARACENI A, HANKS G, KAASA S BENNETT MI, BRUNELLI C, CHERNY N, DALE O, DE CONNO F, FALLON M, HANNA M, HAUGEN DF, JUHL G, KING S, KLEPSTAD P, LAUGSAND EA, MALTONI M, MERCADANTE S, NABAL M, PIGNI A, RADBRUCH L, REID C, SJOGREN P, STONE PC, TASSINARI D, ZEPPETELLA G; EUROPEAN PALLIATIVE CARE RESEARCH COLLABORATIVE (EPCRC); EUROPEAN ASSOCIATION FOR PALLIATIVE CARE (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidencebased recommendations from the EAPC. Lancet Oncol 2012; 13: 58-68.
6. RIPAMONTI CI, SANTINI D, MARANZANO E, BERTI M, ROILA F; ESMO GUIDELINES WORKING GROUP. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012; 23: vii139-154.
7. CHEUNG CW, QIU Q, CHOI SW, MOORE B, GOUCKE R, IRWIN M. Chronic opioid therapy for chronic noncancer pain: a review and comparison of treatment guidelines. Pain Physician 2014; 17: 401-414.
8. http://www.unodc.org/documents/wdr2014/World-Drug-Report-2014-web.pdf
9. PORTER J, JICK H. Addiction rare in patients treated with narcotics. N Engl J Med 1980; 302: 123.
10. FISHBAIN DA, COLE B, LEWIS J, ROSOMOFF HL, ROSOMOFF RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008; 9: 444-459.
11. TRESCOT AM, HELM S, HANSEN H, BENYAMIN R, GLASER SE, ADLAKA R, PATEL S, MANCHIKANTI L. Opioids in the management of chronic non-cancer pain. Pain Physician 2008; 11: S5-S62.
12. WEISSMAN DE, HADDOX JD. Opioid pseudoaddiction- an iatrogenic syndrome. Pain 1989; 36: 363-366.
13. NIIKURA K, NARITA M, BUTELMAN ER, KREEK MJ AND SUZUKI T. Neurophatic and chronic pain stimuli downregulate central mu-opioid and dopaminergic transmission. Trends Pharmacol Sci 2010; 31: 299-305.
14. FRANKLIN GM, AMERICAN ACADEMY OF NEUROLOGY. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology 2014; 83: 1277-1284.
15. MOORMAN-LI R, MOTYCKA CA, INGE LD, CONGDON JM, HOBSON S, POKROPSKI B. A review of abuse-deterrent opioids for chronic non-malignant pain. P T 2012; 37: 412-418.
16. MANCHIKANTI L, BENYAMIN R, DATTA S, VALLEJO R, SMITH H. Opioids in chronic noncancer pain. Expert Rev Neurother 2010; 10: 775-789.
17. ALEXANDER L, MANNION RO, WEINGARTEN B, FANELLI RJ, STILES GL. Development and impact of prescription opioid abuse deterrent formulation technologies. Drug Alcohol Depend 2014; 138: 1-6.
18. CICERO TJ, ELLIS MS. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States Lessons Learned From Oxy- Contin. JAMA Psychiatry 2015; 72: 424-430.
19. HOJSTED J, SJOGREN P, HOJSTED J, SJOGREN P. Addiction to opioids in chronic pain patients: A literature review. Eur J Pain 2007; 11: 490-518.
20. WORLD HEALTH ORGANIZATION. WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses, 2012.
21. RIPAMONTI CI, BOSSI P, SANTINI D, FALLON M. Pain related to cancer treatments and diagnostic procedures: a no man's land? Ann Oncol 2014; 25: 1097-1106.
22. MAMMUCARI M, LAZZARI M, MAGGIORI E, GAFFORIO P, TUFARO G, BAFFINI S, MAGGIORI S, PALOMBO E, DE MEO B, SABATO AF. Role of the informed consent, from mesotherapy to opioid therapy. Eur Rev Med Pharmacol Sci 2014; 18: 566-574.